Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick FDA review for depression treatment:

This article was originally published in Clinica

Executive Summary

The US FDA has told Cyberonics that it will review the company's premarket approval application for a nerve stimulator to treat depression under expedited review status. The Houston, Texas-based company has yet to start its randomised clinical trial of the NCP system, but has submitted an investigational device exemption with the FDA. The trial is likely to take two to three years to complete, said the company. The NCP device is already sold in the US to treat epilepsy and has proved popular with physicians (see Clinica No 812, p 13).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel